Becton, Dickinson and Company
NYSE:BDXMedical - Instruments & Supplies
+$2.36 today
- Market cap
- $58.86B
- Beta
- 0.28
- P/E (TTM)
- 35.5
- EPS (TTM)
- $4.06
- Dividend yield
- 2.60%
Volume 1.32M
Average 2.76M
BDX Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Becton, Dickinson and CompanyNYSE: BDX
Accumulated OCI · Q4 FY2026 · quarter ended Sep 2026
Accumulated OCI turns positive
Q4 FY2026 Accumulated OCI was $0, compared with -$1.87B a year earlier.
Context
- Accumulated OCI amounted to 0.0% of total assets at the end of Q4 FY2026, down 3.4 pp from a year earlier.
- Accumulated OCI increased in 1 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether Accumulated OCI keeps rising in the next quarterly balance sheet after a +100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2026
- 0 USD
- Year-over-year change
- +100.0%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2026 | 2026-09-30 | 0 | +100.0% |
| FY2025 | 2025-09-30 | (1.87B) | -8.0% |
| FY2024 | 2024-09-30 | (1.73B) | -11.9% |
| FY2023 | 2023-09-30 | (1.55B) | -4.0% |
| FY2022 | 2022-09-30 | (1.49B) | — |
Accumulated OCI vs competitors
How BDX compares with its peers on the latest reported figures
- BDX's Sep 2026 Accumulated OCI of $0 is the highest of the 11 companies compared; the peer median is -$283.49M.
- Its year-over-year change of +100.0% is the highest of 11, against a peer median of -6.6%.
- Accumulated OCI amounts to 0.0% of total assets for BDX, versus a peer median of 4.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $0 | +100.0% | — | 0.0% | |
| Mar 2026 | -$120K | -463.6% | — | 0.0% | |
| Sep 2026 | -$10.52M | -182.8% | — | — | |
| Jun 2026 | -$43.34M | -32.8% | — | 1.1% | |
| Jun 2026 | -$140.4M | -58.3% | — | 3.4% | |
| Jun 2026 | -$276.98M | -7.1% | — | 4.1% | |
| Mar 2026 | -$290M | +5.9% | — | 28.2% | |
| Jun 2026 | -$669M | -6.0% | — | 4.7% | |
| Jul 2026 | -$3.76B | +18.4% | — | 4.0% | |
| Jun 2026 | -$3.82B | -1.9% | — | 19.3% | |
| Jun 2026 | -$6.21B | +5.5% | — | 5.7% | |
| Peer median (excluding BDX) | -$283.49M | -6.6% | — | 4.1% | |
Competitors are the stored peer set for BDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 | FY2026 Sep 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.16B | 1.42B | 1.86B | 851M | 725M |
| Short-term Investments | 8M | 8M | 445M | 8M | 8M |
| Net Receivables | 2.19B | 2.53B | 3.03B | 2.99B | 2.77B |
| Inventory | 3.22B | 3.27B | 3.84B | 3.89B | 3.19B |
| Other Current Assets | 1.56B | 1.45B | 1.29B | 1.51B | 1.62B |
| Total Current Assets | 8.14B | 8.68B | 10.47B | 9.26B | 8.32B |
| Property, Plant & Equipment (Net) | 6.01B | 6.56B | 6.82B | 7B | 6.19B |
| Goodwill | 24.62B | 24.52B | 26.47B | 33.02B | 33.62B |
| Intangible Assets | 12.31B | 10.95B | 10.92B | 2.99B | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.85B | 2.08B | 2.62B | 3.06B | 2.66B |
| Total Non-current Assets | 44.79B | 44.1B | 46.82B | 46.07B | 42.47B |
| Total Assets | 52.93B | 52.78B | 57.29B | 55.33B | 50.79B |
| Account Payables | 1.7B | 1.64B | 1.9B | 1.97B | 0 |
| Short-term Debt | 2.3B | 1.26B | 2.31B | 1.56B | 944M |
| Tax Payables | 157M | 139M | 168M | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.49B | 2.49B | 3.33B | 4.45B | 0 |
| Total Current Liabilities | 7.81B | 6.64B | 8.96B | 8.31B | 944M |
| Long-term Debt | 14.27B | 15.15B | 18.61B | 17.62B | 13.42B |
| Deferred Tax Liabilities | 2.67B | 2.45B | 2.07B | 0 | 2.2B |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 2.51B | 2.33B | 1.1B | 4B | 0 |
| Total Non-current Liabilities | 19.84B | 20.34B | 22.44B | 21.62B | 15.62B |
| Total Liabilities | 27.65B | 26.98B | 31.4B | 29.94B | 26.11B |
| Common Stock | 365M | 371M | 371M | 371M | 0 |
| Retained Earnings | 15.16B | 15.54B | 16.14B | 16.62B | 0 |
| Accumulated OCI | (1.49B) | (1.55B) | (1.73B) | (1.87B) | 0 |
| Other Stockholders Equity | 23M | 24M | 25M | 25M | 50.79B |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 25.28B | 25.8B | 25.89B | 25.39B | 24.68B |
| Total Debt | 16.95B | 16.82B | 21.59B | 19.18B | 14.37B |
| Net Debt | 15.79B | 15.34B | 19.73B | 18.33B | 13.64B |
Becton, Dickinson and Company
NYSE:BDX
Intrinsic Alpha fair value
Locked
Current Price
$216.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.